Northwire Canada EditionTuesday, July 14, 2026
Northwire
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Financings Routine +

Apolo V files filing statement for QT

TelyRx QT Filing Clears Final Hurdles as Financing Target Slashes to $20M

Executive Summary
  • Apolo V Acquisition Corp. filed a formal filing statement on March 25, 2026, detailing its proposed Qualifying Transaction (QT) with TelyRx Inc. and related entities.
  • The transaction is structured as a reverse takeover, with TelyRx as the surviving entity. The combined company will list on the Toronto Stock Exchange under the ticker TELY.
  • A concurrent private placement via TelyRx Finco Inc. is structured as a best-efforts offering of 6,091,111 to 9,136,666 subscription receipts at $4.50 each, targeting gross proceeds of US$20 million (minimum) to US$30 million (maximum).
  • Both the TSX-V and TSX have granted conditional approvals. The transaction is expected to close on or around March 31, 2026, at which point trading of Apolo V shares will resume under the new ticker.
  • This filing follows the March 6, 2026 shareholder approval meeting, where all resolutions passed with 98.6% to 100% support.
Material Impact
  • The filing is a procedural, expected milestone that removes the final administrative hurdle before closing. It does not introduce new operational or financial data.
  • The most notable deviation from prior announcements is the reduction in the private placement target from the originally pitched US$40 million to US$46 million down to a US$20 million to US$30 million range. This signals either constrained institutional appetite, a recalibrated capital requirement, or both.
  • Given the company's negative equity position and high liability load, the smaller raise tightens the post-merger financial runway. The impact is incrementally positive for deal certainty but materially neutral regarding fundamental risk reduction.
AFV · Price
Company Overview
  • Apolo V is a Capital Pool Company (CPC) shell executing a reverse takeover with TelyRx Inc., a digital health platform focused on streamlining prescription medication access through telehealth and e-pharmacy services.
  • The flagship project is the TelyRx commercial platform, which generated US$28.61 million in revenue over the nine months ended September 30, 2025.
  • Despite top-line traction, the platform remains unprofitable, reporting a net loss of US$2.33 million for the same period. The business model relies on scaling user acquisition while managing high operational and regulatory overhead.
Read the original news release →

More from Apolo V Acquisition Corp